22Mar/13

Research and Markets: Liver Transplantation – Pipeline Review, H1 2013 – The Herald | HeraldOnline.com

Research and Markets: Liver Transplantation – Pipeline Review, H1 2013
The Herald | HeraldOnline.com
Global Markets Direct’s, ‘Liver Transplantation – Pipeline Review, H1 2013′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Liver Transplantation, complete with latest

and more »

22Mar/13

GE Healthcare (GE): FDA Approves Adreview For Cardiac Risk Evaluation In … – iStockAnalyst (press release)


iStockAnalyst (press release)

GE Healthcare (GE): FDA Approves Adreview For Cardiac Risk Evaluation In
iStockAnalyst (press release)
(NYSE: GE) said its unit GE Healthcare’s AdreView (Iobenguane I 123 Injection) has received approval from the U.S. Food and Drug Administration (FDA) for cardiac risk evaluation in heart failure patients. AdreView is approved for the scintigraphic
GE Healthcare Says FDA Approves Of A New Indication For AdreViewRTT News

all 2 news articles »

22Mar/13

600th Heart Attack Patient Recruited into Phase III CicloMulsion(R) CIRCUS Trial – PharmaLive (press release) (subscription)

600th Heart Attack Patient Recruited into Phase III CicloMulsion(R) CIRCUS Trial
PharmaLive (press release) (subscription)
NeuroVive, a leading mitochondrial medicine company, announces that the 600th patient has been recruited to a pivotal Phase III European, multi-center trial (CIRCUS trial) assessing CicloMulsion® (a special formulation of cyclosporine for acute cardiac

and more »